Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE-TB: NGS-guided Regimens for MDR-TB
NCT03604848Unknown
- Sponsor
- Huashan Hospital
- Start
- Aug 2018
- Primary completion
- Aug 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pyrazinamide, amikacin, moxifloxacin, prothionamide, d-cycloserine and 3 more in multidrug-resistant tuberculosis (MDR-TB) (4 arms), sponsored by Huashan Hospital. Primary endpoint: Efficacy of NGS-guided treatment. Status: unknown.
02
Drugs
pyrazinamideamikacinmoxifloxacinprothionamided-cycloserine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT03604848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604848.